1	Un	Un		C0205447_1	calificador_1	0-2	398_QUEST_clinical_caseMIR	SENT1	-	-
2	hombre	hombre	NCMS000	C0025266#C0086418#C0043210	persona#organismo_vivo	3-9	398_QUEST_clinical_caseMIR	SENT1	-	-
3	de	de	SPS00	C0332285	atributo	10-12	398_QUEST_clinical_caseMIR	SENT1	-	-
4	46	46		-	-	13-15	398_QUEST_clinical_caseMIR	SENT1	-	-
5	años	año	NCMP000	C0439234	calificador	16-20	398_QUEST_clinical_caseMIR	SENT1	-	-
6	con	con	SPS00	C0332287	atributo	21-24	398_QUEST_clinical_caseMIR	SENT1	-	-
7	trastorno	trastorno	NCMS000	C0005586_1	trastorno_1	25-34	398_QUEST_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
8	bipolar	bipolar	NC00SC0	C0005586_2	trastorno_2	35-42	398_QUEST_clinical_caseMIR	SENT1	I-Grp_Enfermedad	-
9	es	ser	VSIP3S0	-	-	43-45	398_QUEST_clinical_caseMIR	SENT1	-	-
10	llevado	llevar	VMP00SM	-	-	46-53	398_QUEST_clinical_caseMIR	SENT1	-	-
11	a	a	SPS00	-	-	54-55	398_QUEST_clinical_caseMIR	SENT1	-	-
12	urgencias	urgencia	NCFP000	C0439609	calificador	56-65	398_QUEST_clinical_caseMIR	SENT1	-	-
13	tras	tras	SPS00	-	-	66-70	398_QUEST_clinical_caseMIR	SENT1	-	-
14	una	una		C0205447_1	calificador_1	71-74	398_QUEST_clinical_caseMIR	SENT1	-	-
15	sobreingesta	sobreingesta	NCFS000	-	-	75-87	398_QUEST_clinical_caseMIR	SENT1	-	-
16	de	de	SPS00	C0332285	atributo	88-90	398_QUEST_clinical_caseMIR	SENT1	-	-
17	carbonato	carbonato	NCMS000	C0085217_1	sustancia_1	91-100	398_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
18	de	de	SPS00	C0085217_2	sustancia_2	101-103	398_QUEST_clinical_caseMIR	SENT1	-	-
19	litio	litio	NCMS000	C0085217_3	sustancia_3	104-109	398_QUEST_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
20	.	.	Fp	-	-	109-110	398_QUEST_clinical_caseMIR	SENT1	-	-

1	En	en	SPS00	C1720294#C0332285	calificador#atributo	111-113	398_QUEST_clinical_caseMIR	SENT2	-	-
2	la	el	DA0FS0	-	-	114-116	398_QUEST_clinical_caseMIR	SENT2	-	-
3	exploración	exploración	NCFS000	C1280903	procedimiento	117-128	398_QUEST_clinical_caseMIR	SENT2	-	-
4	destaca	destacar	VMIP3S0	-	-	129-136	398_QUEST_clinical_caseMIR	SENT2	-	-
5	temblor	temblor	NCMS000	C0040822#C1527384_1	hallazgo_1	137-144	398_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
6	intenso	intenso	AQ0MS0	C0205178	calificador	145-152	398_QUEST_clinical_caseMIR	SENT2	B-Calificador	-
7	,	,	Fc	-	-	152-153	398_QUEST_clinical_caseMIR	SENT2	-	-
8	ataxia	ataxia	NCFS000	C0004134	hallazgo	154-160	398_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
9	,	,	Fc	-	-	160-161	398_QUEST_clinical_caseMIR	SENT2	-	-
10	disartria	disartria	NCFS000	C0013362	hallazgo	162-171	398_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
11	,	,	Fc	-	-	171-172	398_QUEST_clinical_caseMIR	SENT2	-	-
12	mioclonías	mioclonías	NC00KE0	-	-	173-183	398_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
13	y	y	CC	C1706368	calificador	184-185	398_QUEST_clinical_caseMIR	SENT2	-	-
14	fasciculaciones	fasciculaciones	NCFP000	-	-	186-201	398_QUEST_clinical_caseMIR	SENT2	B-Grp_Enfermedad	-
15	.	.	Fp	-	-	201-202	398_QUEST_clinical_caseMIR	SENT2	-	-

1	La	el	DA0FS0	-	-	203-205	398_QUEST_clinical_caseMIR	SENT3	-	-
2	litemia	litemia	NCFS000	-	-	206-213	398_QUEST_clinical_caseMIR	SENT3	-	-
3	es	ser	VSIP3S0	-	-	214-216	398_QUEST_clinical_caseMIR	SENT3	-	-
4	de	de	SPS00	C0332285	atributo	217-219	398_QUEST_clinical_caseMIR	SENT3	-	-
5	4,1	4,1		-	-	220-223	398_QUEST_clinical_caseMIR	SENT3	-	-
6	mEq	miliequivalente_(10-3_mol_dividido_por_la_valencia)	NC00YL0	-	-	224-227	398_QUEST_clinical_caseMIR	SENT3	-	-
7	/	/	Fh	-	-	227-228	398_QUEST_clinical_caseMIR	SENT3	-	-
8	L	l	NCFS000	-	-	228-229	398_QUEST_clinical_caseMIR	SENT3	-	-
9	(	(	Fpa	-	-	230-231	398_QUEST_clinical_caseMIR	SENT3	-	-
10	toxicidad	toxicidad	NCFS000	C0600688	-	231-240	398_QUEST_clinical_caseMIR	SENT3	-	-
11	>	>	Fz	-	-	241-242	398_QUEST_clinical_caseMIR	SENT3	-	-
12	1,6	1,6		-	-	243-246	398_QUEST_clinical_caseMIR	SENT3	-	-
13	mEq	miliequivalente_(10-3_mol_dividido_por_la_valencia)	NC00YL0	-	-	247-250	398_QUEST_clinical_caseMIR	SENT3	-	-
14	/	/	Fh	-	-	250-251	398_QUEST_clinical_caseMIR	SENT3	-	-
15	L	l	NCFS000	-	-	251-252	398_QUEST_clinical_caseMIR	SENT3	-	-
16	)	)	Fpt	-	-	252-253	398_QUEST_clinical_caseMIR	SENT3	-	-
17	.	.	Fp	-	-	253-254	398_QUEST_clinical_caseMIR	SENT3	-	-

1	¿	¿	Fia	-	-	255-256	398_QUEST_clinical_caseMIR	SENT4	-	-
2	Cuál	cuál	PT0CS000	-	-	256-260	398_QUEST_clinical_caseMIR	SENT4	-	-
3	de	de	SPS00	C0332285	atributo	261-263	398_QUEST_clinical_caseMIR	SENT4	-	-
4	las	el	DA0FP0	-	-	264-267	398_QUEST_clinical_caseMIR	SENT4	-	-
5	siguientes	siguiente	AQ0CP0	C0332282	atributo	268-278	398_QUEST_clinical_caseMIR	SENT4	-	-
6	opciones	opción	NCFP000	-	-	279-287	398_QUEST_clinical_caseMIR	SENT4	-	-
7	terapéutica	terapéutico	AQ0FS0	-	-	288-299	398_QUEST_clinical_caseMIR	SENT4	-	-
8	estaría	estar	VAIC1S0	-	-	300-307	398_QUEST_clinical_caseMIR	SENT4	-	-
9	más	más	RG	C0205172	calificador	308-311	398_QUEST_clinical_caseMIR	SENT4	-	-
10	indicada	indicar	VMP00SF	-	-	312-320	398_QUEST_clinical_caseMIR	SENT4	-	-
11	?	?	Fit	-	-	320-321	398_QUEST_clinical_caseMIR	SENT4	-	-
12	:	:	Fd	-	-	321-322	398_QUEST_clinical_caseMIR	SENT4	-	-
13	.	.	Fp	-	-	322-323	398_QUEST_clinical_caseMIR	SENT4	-	-

